The use of data mining methods to screen collections of Individual Case Safety Reports for important reporting patterns has gone from proof-of-concept to widespread use
Horsham, PA (Vocus) October 2, 2009
The 2nd DIA Conference on Signal Detection and Data Mining will be held from November 16-18, 2009 in New York, NY. This three-day conference will explore address all aspects of signal detection and data mining, including methodologies, clinical interpretation, and international harmonization initiatives.
Experts will discuss:
- Future for analysis of spontaneous reports and other healthcare data with potential applicability to pharmacovigilance
- Signal detection successes resulting from data mining spontaneous reports, with a discussion of the pitfalls, evaluation and validation of the methods and real-world implementation
- Update on the networks of pharmacoepidemiology and the use of longitudinal/observational databases for signal detection purposes
- Update on CIOMS VIII working group on signal detection and management
- FDA Sentinel Initiative and the Observational Medical Outcomes Partnership (OMOP)
"The use of data mining methods to screen collections of Individual Case Safety Reports for important reporting patterns has gone from proof-of-concept to widespread use," says Program Committee Member Andrew Bate, PhD, Director, Quantitative Epidemiology, Pfizer Inc. "Currently, there is a growing interest in screening other sources of real-world medical information for emerging safety issues and developing computational methods which do not rely on disproportionality analysis. This conference will bring together an international group of experts to review current state-of-the-art thinking on the future developments in data mining and signal detection and a vision of how public health and patient safety issues will be detected faster and more effectively in the future."
Click here to register.
About the Drug Information Association (DIA)
DIA serves more than 30,000 professionals involved in the biopharmaceutical industry and regulatory affairs worldwide. Through its domestic and international meetings, training courses, workshops and webinars, DIA provides a neutral global forum for the exchange of information critical to the advancement of the drug discovery and lifecycle management processes. Headquartered in Horsham, PA, USA, and with offices in Basel, Switzerland, Tokyo, Japan, Mumbai, India, and Beijing, China, the Association is led by its volunteer-based Board of Directors and executive management team. For more information, visit http://www.diahome.org or call 215-442-6100.
Contact: Joe Krasowski
# # #